Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis | Zendy

Anis A. Khan | Zendy; Teri R. Slifer | Zendy; Fausto G. Araujo | Zendy; R J Polzer | Zendy; Jack S. Remington | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis

Author(s) -

Anis A. Khan,

Teri R. Slifer,

Fausto G. Araujo,

R J Polzer,

Jack S. Remington

Publication year - 1997

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.41.5.893

Subject(s) - trovafloxacin , sulfadiazine , toxoplasmosis , pyrimethamine , toxoplasma gondii , pharmacology , medicine , clarithromycin , clindamycin , atovaquone , antibacterial agent , antibiotics , immunology , microbiology and biotechnology , biology , malaria , antibody , plasmodium falciparum

Current therapy for toxoplasmosis with a synergistic combination of pyrimethamine plus sulfadiazine or pyrimethamine plus clindamycin is not always efficacious and is frequently discontinued due to intolerable toxic effects in immunocompromised individuals, particularly those with AIDS. Trovafloxacin, a new fluoroquinolone with potent activity against Toxoplasma gondii, was examined for potential synergistic activity when combined with other drugs used for treatment of human toxoplasmosis. Combinations of trovafloxacin with clarithromycin, pyrimethamine, or sulfadiazine demonstrated significantly enhanced activities compared to those observed with each drug alone. Our results suggest that combinations of trovafloxacin and other anti-toxoplasma drugs should be further explored for treatment of toxoplasmosis in humans.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research